Carlos Cruchaga, PhD, Washington University School of Medicine, St Louis, MO, and his team are focused on the identification and characterization of genetic variants implicated in Alzheimer’s disease (AD). By leveraging multi-tissue multi-omic data for deep molecular profiling, the hope to identify novel variants, drug targets, and biomarkers. Currently, the team are using genome-wide association studies and exome-chip data to identify variants/pathways associated with cerebrospinal (CSF) levels of known AD biomarkers. Dr Cruchaga explains how Mendelian Randomization and a novel network-based approach will be tied into these findings to identify causal variants involved in AD, and analytes that can predict AD risk, age at onset, or rate of disease progression. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.
Disclosures
CC has received research support from: Biogen, EISAI, Alector and Parabon. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. CC is a member of the advisory board of Vivid genetics, Halia Therapeutics and ADx Healthcare.
